Chairman, Intensive Care Department, Medical Director, Respiratory Services, Professor, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, King Abdulaziz Medical City Riyadh, Kingdom of Saudi Arabia.
Dr. Arabi is recognized leader in critical care research and in the area of randomized controlled trial sepsis, mechanical ventilation, Coronavirus disease (COVID-19), and Middle East respiratory syndrome coronavirus (MERs CoV) research. He has lead multiple randomized controlled trials that were published in the leading medical journals. He has conducted the PREVENT trial (“Prophylaxis of Thromboembolism in Critically Ill Patients Using Combined Intermittent Pneumatic Compression and Pharmacologic Prophylaxis versus Pharmacologic Prophylaxis Alone: A Multicenter Randomized Controlled Trial”), MIRACLE trial (“MERS-CoV Infection Treated with a Combination of Lopinavir/Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-Blind Randomized”) PERMIT trial (The Impact of Permissive Underfeeding versus Target Enteral Feeding on Mortality and Morbidity in Adult Critically Ill Patients: a Multicenter Randomized Controlled Trial”), all published in the New England Journal of Medicine (NJEM). He collaborated with the Australian and New Zealand Intensive Care Society (ANZICS), and the Canadian Critical Care Trials Group (CCCTG) on multiple major controlled trials.
Dr. Arabi leadership has been recognized in multiple awards; including the Saudi Universities Excellence Award in Scientific Productivity per Web of Science Medical Sciences and Ministry of Health Pioneer Research Award (2019), Distinguished Scientist Award from Almarai (2017), Distinguished Scientist Award from Almarai Award for Innovation (2017), 2nd Annual Lifetime Achievement Award from the Saudi Critical Care Society (SCCS) (2013), Bary A. Shapiro